HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.

Monday, 18 June 2012

NICE says yes to rivaroxaban for DVTs

After a previous ‘minded no’ with a request for further evidence, NICE has recommended rivaroxaban (Xarelto, Bayer Healthcare) as an option for treating deep vein thrombosis and preventing recurrent deep vein thrombosis and pulmonary embolism in adults diagnosed with acute deep vein thrombosis (DVT).  This and the spate of other minded no’s was previously reported in the HEDS Blog.

The Evidence Rview Group were ScHARR-TAG, with Sue Harnan, Rachid Rafia, Edith Poku, John Stevens, Matt Stevenson and Ruth Wong doing the work.  As well as undertaking the original appraisal, the group produced a 28 page examination of the additional evidence provided by the manufacturer, which is available here.